论文部分内容阅读
目的将布托啡诺及地佐辛分别与依托咪酯配伍用于无痛人流进行疗效比较。方法选取2012年11月—2013年8月在我院接受无痛人流术患者共113例,随机分为布托啡诺+依托咪酯组(A组)与地佐辛+依托咪酯组(B组)二组,A组静脉注射布托啡诺10μg/kg,2min后静脉注射依托咪酯0.3mg/kg,B组先静脉注射0.05mg/kg地佐辛,5min后再静脉注射依托咪酯0.3mg/kg。二组患者术前均用托烷司琼2mg静脉注射止吐。记录患者围术期生命体征变化,呼吸抑制的发生率,镇痛效果以及麻醉维持时间、苏醒时间、定向力恢复时间和不良反应。结果生命体征变化,呼吸抑制的发生率,不良反应发生率二组比较差异无统计学意义,二组均获得了满意的术中术后镇痛效果;B组定向力恢复时间和离院时间明显短于A组(P<0.01)。结论布托啡诺及地佐辛分别联合依托咪酯应用于无痛人流术,镇静镇痛效果确切,生命体征平稳,呼吸抑制的发生率低,不良反应的发生率低。但地佐辛联合依托咪酯的应用,患者苏醒质量高,定向力恢复时间更快。
Objective To compare the efficacy of butorphanol and dezocine with etomidate for painless patients. Methods A total of 113 patients with painless abortion in our hospital from November 2012 to August 2013 were randomly divided into two groups: butorphanol and etomidate group (group A) and dezocine + etomidate group Group B), group A received intravenous injection of butorphanol 10μg / kg, intravenous injection of etomidate 0.3mg / kg 2 minutes later, group B intravenous injection of 0.05mg / kg dezocine intravenously 5 minutes later, intravenous injection of etomidate Ester 0.3 mg / kg. Two groups of patients with tropisetron 2mg before intravenous antiemetic. The change of perioperative vital signs, the incidence of respiratory depression, analgesic effect, anesthesia maintenance time, recovery time, recovery time and adverse reactions were recorded. Results The changes of vital signs, the incidence of respiratory depression and the incidence of adverse reactions were not statistically different between the two groups, and satisfactory postoperative analgesic effects were obtained in both groups. The recovery time and departure time of group B in group B were significantly higher Shorter than A group (P <0.01). Conclusions Butorphanol and dezocine combined with etomidate respectively for painless abortion have definite effects of sedation and analgesia, steady vital signs, low incidence of respiratory depression and low incidence of adverse reactions. But dezocine combined with etomidate application, patients wake up high quality, faster recovery of directional force.